A treatment combining anti-CD47 mAb with TTI-621, a SIRPα-Fc fusion protein used to prevent SIRPα:CD47 interaction, was reported to promote the phagocytosis of tumor cells in a B-cell lymphoma mouse model [239,240]. Here, SIRPA is linked to B-cell non-Hodgkin lymphoma.